Nalbuphine

CHEMBL895 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

357.4 g/mol

LogP

0.2

Phase

4

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

आणविक भार

357.4000 g/mol

LogP

0.20

TPSA

73.20 Å²

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अनिद्रा अस्थमा उच्च रक्तचाप जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर दर्द प्रबंधन दीर्घकालिक दर्द नॉन-स्मॉल सेल लंग कैंसर मोटापा ल्यूकेमिया स्तन कैंसर हृदय विफलता

क्रिया का तंत्र

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314

InChI

InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1

Molecular Formula

C21H27NO4

HBD / HBA

3 / 5

घूर्णनीय बंधन

2

भारी परमाणु

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Nalbuphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL895. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5311304. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Nalbuphine PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C21H27NO4

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.